About Alexion
Alexion is a company based in Zurich (Switzerland) founded in 1992 was acquired by Astrazeneca in December 2020. Alexion has raised $8 million across 12 funding rounds from investors including Astrazeneca, Permira and HHS. The company has 2 employees as of March 22, 2024. Alexion has completed 8 acquisitions, including Achillion, Enobia Pharma and LogicBio. Alexion operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Zurich, Switzerland
- Employees 2 as on 22 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alexion Business Services Private Limited
- Date of Incorporation 03 Jun, 2011
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$293.75 K (USD)-59.48as on Mar 31, 2020
-
Net Profit
$49.59 K (USD)53.84as on Mar 31, 2020
-
EBITDA
$67.83 K (USD)38.68as on Mar 31, 2020
-
Total Equity Funding
$8 M (USD)
in 12 rounds
-
Latest Funding Round
$3.61 B (USD), Debt – Conventional
Jun 15, 2018
-
Investors
Astrazeneca
& 7 more
-
Employee Count
2
as on Mar 22, 2024
-
Investments & Acquisitions
Achillion
& 7 more
-
Acquired by
Astrazeneca
(Dec 12, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Alexion
Unlock access to complete
Leadership Team
54 people
Human Resources and Administration
25 people
Sales and Marketing
18 people
Finance and Accounting
16 people
Software Development Team
11 people
Product Management Team
10 people
Regional Team
9 people
Head Team
6 people
Unlock access to complete
Funding Insights of Alexion
Alexion has successfully raised a total of $8M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3.61 billion completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alexion
Alexion has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Permira and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Investments are made in technology, consumer, healthcare, and service sectors.
|
Locked | Locked | Locked | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked |
Investor details for Alexion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alexion
Alexion has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Achillion, Enobia Pharma and LogicBio.
Investment portfolio details for Alexion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Viral vectors are developed for genetic and infectious disease treatments.
|
Locked | Locked | 2013 | Locked | |
|
IgG-mediated autoimmune diseases are treated via Fc receptor-targeting antibodies.
|
Locked | Locked | 2013 | Locked | |
|
De-coppering agents for Wilson disease treatment are developed.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Alexion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alexion
Detailed financials for Alexion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alexion Comparisons
Peer comparison for Alexion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alexion
Alexion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Alexion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alexion
Complete news archive for Alexion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alexion
Alexion was founded in 1992 and raised its 1st funding round 1 year after it was founded.
Alexion is headquartered in Zurich, Switzerland.
Ludwig Hantson is the current CEO of Alexion.
Alexion is a funded company, having raised a total of $8M across 12 funding rounds to date.
As of Mar 22, 2024, the latest employee count at Alexion is 2.
Annual revenue of Alexion is $293.75K as on Mar 31, 2020.
Alexion was founded in 1992 and is based in Zurich, Switzerland. Focus is placed on developing treatments for rare diseases affecting hematology, nephrology, neurology, metabolic, and cardiology areas. Soliris, a terminal complement inhibitor, is utilized for myasthenia gravis management, and Ultomiris addresses hemolytic uremic syndrome. Operations center on pharmaceutical innovation for underserved patient populations in these medical fields.
Alexion's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Alexion has made 8 acquisitions, including Achillion, Enobia Pharma, and LogicBio.
Alexion has 8 investors. Key investors include Astrazeneca, Permira, HHS, Allen & Company, and BB Biotech.